Thus, to confirm the direct contribution of SMYD3 in mediating cancer cell responsiveness to genotoxic drugs, we transiently restored SMYD3 expression in HCT116-SMYD3-KO cells with a construct leading to the synthesis of WT SMYD3 (FLAG-SMYD3-WT) or an enzymatic-inactive mutant (FLAG-SMYD3-F183A). The gene discussed is SMYD3; the disease is cancer.